FLUCURE
Project ID: 259972
Funded under: FP7-HEALTH

Development of novel antiviral drugs against Influenza

From 2010-10-01 to 2014-09-30, closed project

Project details

<table>
<thead>
<tr>
<th>Total cost:</th>
<th>Topic(s):</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUR 7 822 101</td>
<td>HEALTH.2010.2.3.3-4 - Novel therapeutics against influenza. FP7-INFLUENZA-2010</td>
</tr>
<tr>
<td>EU contribution:</td>
<td>Funding scheme:</td>
</tr>
<tr>
<td>EUR 5 982 600</td>
<td>CP-FP - Small or medium-scale focused research project</td>
</tr>
<tr>
<td>Coordinated in:</td>
<td></td>
</tr>
<tr>
<td>Sweden</td>
<td></td>
</tr>
</tbody>
</table>

Objective

Influenza viruses cause a highly contagious respiratory disease in both humans and animals. Typically, influenza spreads worldwide in seasonal epidemics resulting in an estimated 3 to 5 million cases of severe illness and 250,000 to 500,000 deaths annually. In addition to these seasonal epidemics there have been several pandemics since the early 1900's, where highly virulent strains emerged, the most devastating being the ‘Spanish Flu’ of 1918, which caused 20-40 million deaths globally. Vaccination is currently the primary means of controlling the spread of influenza virus infections but due to the virus’s notorious ability to mutate, new vaccines must be developed each year. There are a few antiviral drugs that are currently on the market; however, their therapeutic potential is restricted through rapid appearance of drug-resistant viruses during treatment. Thus, the need for novel effective drugs against influenza is evident. The FLUCURE project aims at developing innovative, first-in-class therapeutics against influenza by targeting the viral ribonucleoprotein complex, which is replication core of the virion and a major contributor to viral virulence. The high level of conservation combined with slow mutation rates of the ribonucleoprotein complex should result in therapeutics with broad viral strain specificity associated with a reduced risk for developing resistance. FLUCURE builds further on two successful EU-FP7 drug discovery projects, FLUINHIBIT and FluDrugStrategy, both targeting specific but different protein-protein interactions of the viral ribonucleoprotein complex with small molecule inhibitors. A consortium of 10 partners with the required complementary skills will progress the lead candidates from these two projects synergistically through lead optimization and preclinical development phases, with the final objective to deliver one or more drug candidates suitable for entering clinical development within 4 years.

Related information

<table>
<thead>
<tr>
<th>Report Summaries</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Final Report Summary - FLUCURE (Development of novel antiviral drugs against Influenza)</td>
<td></td>
</tr>
</tbody>
</table>
Coordinator

VIRONOVA AB
Gavlegatan 22
11330 STOCKHOLM
Sweden

EU contribution: EUR 1 247 200

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

Administrative contact: Charlotta Hjerpe
Tel.: +46 8 7026790
Fax: +46 8 7026791
Contact the organisation

Participants

BEACTICA AB
VIRDINGS ALLE 2
754 50 UPPSALA
Sweden

EU contribution: EUR 707 600

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

Administrative contact: Per Kaellblad
Tel.: +46 18560880
Fax: +46 18506808
Contact the organisation

PIKE PHARMA GMBH
TECHNOPARKSTRASSE 1
CH-8005 ZUERICH
Switzerland

EU contribution: EUR 1 383 000

Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)

Administrative contact: Ulrich Kessler
Tel.: +41 79 7784884
Fax: +41 44 2002112
Contact the organisation
UNIVERSITAETSKLINIKUM FREIBURG
HUGSTETTER STRASSE 49
79106 FREIBURG
Germany
EU contribution: EUR 771 000

Activity type: Higher or Secondary Education Establishments
Administrative contact: Juergen Dreyer
Tel.: +49 761 270 2081
Fax: +49 761 270 1889
Contact the organisation

INSTITUTE OF ORGANIC CHEMISTRY WITH CENTRE OF PHYTOCHEMISTRY - BULGARIAN ACADEMY OF SCIENCES
Acad Georgi Bonchev street bld 9
1113 SOFIA
Bulgaria
EU contribution: EUR 208 800

Activity type: Higher or Secondary Education Establishments
Administrative contact: Lilia Viteva
Tel.: +359 2 96 09 114
Fax: +3592 8 700 225
Contact the organisation

VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
De Boelelaan 1105
1081 HV AMSTERDAM
Netherlands
EU contribution: EUR 803 400

Activity type: Higher or Secondary Education Establishments
Administrative contact: Yvonne Kops
Tel.: +31 20 5987500
Fax: +31 20 5987448
Contact the organisation
VILNIAUS UNIVERSITETAS
UNIVERSITETO G. 3
01513 VILNIUS
Lithuania

**EU contribution:** EUR 192 000

See on map

**Activity type:** Higher or Secondary Education Establishments

**Administrative contact:** Vida Lapinskaite
Tel.: +370 5 2687164
Fax: +370 5 2687009

Contact the organisation

PHARMACELSUS GMBH
SCIENCE PARK 2
66123 SAARBRUCKEN
Germany

**EU contribution:** EUR 393 600

**Activity type:** Private for-profit entities (excluding Higher or Secondary Education Establishments)

**Administrative contact:** Reiner Class
Tel.: +4968139467528
Fax: +4968139467511

Contact the organisation

UNIVERSITA DEGLI STUDI DI SIENA
VIA BANCHI DI SOTTO 55
53100 SIENA
Italy

**EU contribution:** EUR 276 000

See on map

**Activity type:** Higher or Secondary Education Establishments

**Administrative contact:** Maurizio Botta
Tel.: +39 0577 234306
Fax: +39 0577 234333

Contact the organisation

STICHTING VU
DE BOELELAAN 1105
1081 HV AMSTERDAM
Netherlands

See on map

**Activity type:** Higher or Secondary Education Establishments

**Administrative contact:** Yvonne Kops
Tel.: +31 20 5987500

Contact the organisation

**Last updated on** 2019-08-01